We help unlock the untapped potential of phages
for phage therapy and biocontrol by empowering
people to access, use and build upon
the world’s phage knowledge.
Read our mission.
⬢-{ Phage Pheed }-⬢
Why don’t we have phage therapy yet? We want to understand why. Come join the fun by tuning into the Podovirus podcast!
🎙️ Most recent episode: Dr. Marisa Azad, infectious disease physician at The Ottawa Hospital, shares her experience leading Canada’s first-ever approved ‘n of 1’ phage therapy treatment for a prosthetic joint infection, and discusses what it took to make this happen!
🎧 Listen: Podovirus on Spotify
🎥 Watch: Podovirus on YouTube
Subscribe to get the next episodes!
🩺 Up next: We’ll be talking to more clinicians, scientists and phage biotech executives about their experiences implementing phage therapy at their institutions, including the challenges and successes they’ve encountered along the way.
Masako Shimamura (Nationwide Children’s Hospital and the Ohio State University) and colleagues published a new paper on dual β-lactam therapy for macrolide-resistant M. abscessus, showing successful treatment of two pediatric cases using multi-drug regimens including meropenem-amoxicillin combinations, with one case requiring additional phage therapy for hardware-associated infection clearance.
Jialin Xiang (Wuhan University) and colleagues published a new paper on type IV pili-mediated archaeal virus mutualism, showing that co-resident temperate viruses SNJ1 and SNJ2 establish tripartite mutualistic interactions with their haloarchaeon host through viral-encoded pili serving as receptors.
Michael Doud (University of California, San Diego) and colleagues published a new paper on AI applications in phage therapy, showing how AI can improve phage-host matching, discover novel phage genes, and guide development of synthetic therapeutic phages.
Kai Wang (Huazhong Agricultural University, China) and colleagues published a new paper on novel trimethoprim resistance genes in phage-plasmids, showing identification of two functional dfrA genes (dfrA50 and dfrA51) that confer trimethoprim resistance and are widely disseminated among pathogenic bacteria.
Dr. Stephen Vaughan (University of Calgary) successfully treated 76-year-old Boyd English’s decade-long antibiotic-resistant hip infection using phage therapy. This is the first PJI phage treatment in Western Canada.
Follow Capsid & Tail, the periodical that reports the latest news from the phage therapy and research community.
In collaboration with
